TERN
NASDAQ HealthcareTerns Pharmaceuticals, Inc. - Common Stock
Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
�� 市场数据
| 价格 | $52.65 |
|---|---|
| 成交量 | 6,348,187 |
| 市值 | 6.08B |
| 贝塔系数 | -0.380 |
| RSI（14日） | 35.8 |
| 200日均线 | $25.11 |
| 50日均线 | $46.00 |
| 52周最高 | $53.19 |
| 52周最低 | $2.37 |
| Forward P/E | -35.78 |
| Price / Book | 5.88 |
🎯 投资策略评分
TERN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (64/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🎈 Over-Hyped (4/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TERN in your text
粘贴任何文章、记录或帖子 — 工具将提取 TERN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.